IL6 and ventilator-associated pneumonia: The introduction of corticosteroid therapy may also reduce the stimulation of the IL-6-dependent HPA axis, limit the anti-inflammatory response, and thus limit the prevalence of VAP in patients with exacerbated inflammation (197).